Slide 1

Thomas Ross, D.O.

Slide 2

Slide 3

Increase understanding of newer contraceptive options Utilize recommendations for indications and contraindications of popular contraceptive options

Slide 4

In 2012, for women ages 15-19 years, the live birth rate was 29.4 per 1,000. This is a record low for U.S. teens and a decrease of 6% from 2011. The decline appears related to a decrease in sexual intercourse and an increase in consistent contraceptive use. Source: CDC

Slide 5

Slide 6

U.S. teen. pregnancy, birth, STI, and abortion rates are substantially higher than other western industrialized nations. Source: CDC

Slide 7

Slide 8

Slide 9

Highly dependent on education and counseling Still best provided by personal interaction

Slide 10

Little recent activity with new products 2 noteworthy options

Slide 11

Slide 12

Slide 13

Slide 14

Slide 15

Slide 16

Slide 17

Slide 18

Slide 19

Slide 20

Slide 21

Adapted from WHO MEC, 4 th Edition

Slide 22

1 a condition with no restriction for the use of the contraceptive method 2 a condition for which the advantages of a method generally outweigh the risks 3 a condition for which the risks of a method usually outweigh the advantages 4 a condition that represents an unacceptable health risk if the contraceptive method is used

Slide 23

Slide 24

Underutilized, but an excellent option for those patients with contraindications to hormonal contraception.

Slide 25

Slide 26

Slide 27

Slide 28

Slide 29

Bosworth MC, et al

Slide 30

Slide 31

Risk of pregnancy increased for women over BMI 25 who used Plan B. Risk of pregnancy after unprotected intercourse was basically the same with or without taking levonorgestrel (5.8% vs. 5.6%) in two randomized trials. Evidence of decreased efficacy was also seen with ulipristal to a small degree.

Slide 32

Glasier A, et al. Can we identify women at risk of pregnancy despite using EC? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84(4):363-367

Slide 33

EC indicated for up to 5 days after unprotected intercourse Works primarily by delaying ovulation a Selective Progesterone Receptor Modulator Side effects similar to Plan B In clinical trial; 1.8% pregnancy rate vs. 2.6% with Plan B (n=844, 852)

Slide 34

New method in development, vaccination against human chorionic gonadotropin (hCG). Antibodies are created by hCG production (when pregnancy occurs), similar to when your body fights an infection. Your immune system attacks the embryo which is producing hCG. The vaccine is effective for approximately one year. Source: Epigee, Feminist Women's Health Center

Slide 35

Proving to be problematic and elusive, but a new technique shows promise.

Slide 36

Several recent non-scientific surveys of men have shown over 50% of those responding state they would be willing to use a reversible contraceptive method. The pharmaceutical companies have been very slow to aggressively pursue what they percieve as a limited market.

Slide 37

The next 3 slides were actually part of a presentation first presented 10 years ago. All 3 options have been unsuccessful, at least so far.

Slide 38

A combination progestin and androgen therapy holds the most promise Organon is testing, in the U.S. and Europe, an etonogestrel subdermal implant with testosterone injections every 4-6 weeks. This will likely be the first MHC approved by the FDA. It is scheduled to be on the market by 2005, but U.S. availability may be 5 years.

Slide 39

An oral pill containing desogesterel and testosterone is also in clinical trials. Results are very promising. The Population Center for Research in Reproduction at the U. of W. in Seattle is testing several male contraceptive methods.

Slide 40

Called the Bright Pill Dr. Haim Breitbart in Tel Aviv is performing early testing on a compound that blocks protein synthesis by sperm, that is essential for penetration thru the eggs cell membrane. A single pill may be effective for 1 to 3 months with no decrease in testosterone production.

Slide 41

Reversible inhibition of sperm under guidance (RISUG) developed in India by Dr. Sujoy Guha is a procedure involving injecting a copolymer of styrene/maleic anhydride (SMA) into both vas deferens tubes. This does not obstruct the tubes, but rather damages the sperm as it moves past it. A solution of sodium bicarbonate can flush out this copolymer and restore fertility.

Slide 42

Some of the men in India have been using RISUG for highly effective contraception for more than 15 years. Reversibility studies have only been done in animals. In 2010, the Parsemus Foundation purchased the rights to develop RISUG in the U.S. The new polymer is called Vasalgel. Clinical trials were expected to start this year.

Slide 43

Kogan P, Wald M. Male Contraception History and Development: Urology Clinics of North America:2014:145- 161 Dr. Wald is a urologist at U. of I.

Slide 44

Slide 45

For everything you do for Iowa women and their families

Slide 46